The Epstein–Barr virus and post‐transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis
- 1 June 2001
- journal article
- review article
- Published by Wiley in Transplant Infectious Disease
- Vol. 3 (2) , 60-69
- https://doi.org/10.1034/j.1399-3062.2001.003002060.x
Abstract
Transplant patients are at particular risk for developing post‐transplant lymphoproliferative disease (PTLD) following administration of immunosuppressive therapy. In many cases the PTLD le...Keywords
This publication has 164 references indexed in Scilit:
- Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomasClinical Transplantation, 1999
- Generic Signals and Specific OutcomesCell, 1999
- Interleukin-12 Expression in B Cells by Transformation with Epstein–Barr VirusBiochemical and Biophysical Research Communications, 1998
- The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevantCancer, 1998
- Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-AHuman Immunology, 1996
- Mediation of Epstein-Barr Virus EBNA2 Transactivation by Recombination Signal-Binding Protein J κScience, 1994
- Expression of genes for the Epstein--Barr virus small RNAs EBER-1 and EBER-2 in Daudi Burkitt's lymphoma cells: effects of interferon treatmentJournal of General Virology, 1992
- Cyclosporin A renders target cells resistant to immune cytolysisEuropean Journal of Immunology, 1991
- Expression of Epstein–Barr Virus Transformation–Associated Genes in Tissues of Patients with EBV Lymphoproliferative DiseaseNew England Journal of Medicine, 1989
- The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replicationCell, 1989